NewsFebruary 26, 2018
CYBERDYNE, INC.
CureApp, Inc.

CYBERDYNE and CureApp form a business and capital alliance~ combining Cybernic Technology and treatment application to promotepersonalized medicine with mobile devices ~CYBERDYNE, INC. [Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai (“Cyberdyne”)] andCureApp, Inc. [Chuo-ku, Tokyo, CEO: Kota Satake (“CureApp”)] announced that they
formed a capital tie-up (Cyberdyneʼs investment in CureApp) and a business alliancetowards promotion of advanced personalized medicine with mobile devices. Cyberdyne
will support the business of CureApp and also combine its Cybernic Technology withtreatment applications of CureApp. Through these endeavor, the two companies aim topromote advanced personalized medicine with mobile devices by utilizing medical Big
Data that are obtained through various Cybernic Devices linked in Internet of
Humans/Internet of Things (“IoH/IoT”).

CureApp is a venture company that was founded in July 2014 by medical doctors todevelop medical devices with “Treatment Application” based on medical evidence.
Treatment Application developed by CureApp allows a doctor to provide off-site, andreal-time treatment-intervention in various aspects of a patientʼs daily life including its
awareness, habits and time schedule. The appropriately can follow it up according tothe patientʼs personal conditions. To realize the first medical service with “the clinicallyeffective application on improvement of diseases” in Japan, CureApp develops
applications for mobile devices, such as “CureApp Smoking Cessation” for treatment ofnicotine addiction and “CureApp NASH” for treatment of non-alcoholic steatohepatitis,“NASH”. Clinical trials and clinical researches are currently in progress to evaluate theclinical effects of the aforementioned applications.

In the field of medicine, Cyberdyne develops innovative products such as HAL for
Medical Use Lower Limb Type that is designed to improve and regenerate the motor

function of its wearer. It also develops Vital Sensor that is designed fordaily monitoringof arterial hardening and cardiac arrhythmias to prevent

lifestyle-related diseases. Furthermore, as one of the center partners of World EconomicthForum 4 Industrial Revolution Center, Cyberdyne is currently working on the Precision
Medicine Project to promote various forms of personalized medicine. In order toimprove the condition of a patient in a true sense, it is necessary to improve theawareness, action and habit of the patient by making intervention in their lives outsideof the hospital. With an aim to promote this advanced personalized IoH/IoT medicine,
the two companies entered into this business and capital alliance. Through this alliance,
Cyberdyne and CureApp will fully utilize the cutting-edge technology to overcome theincrease in medical cost that is caused by the trend of aging and improving longevity.
The two companies aim to contribute to the realization of the society of good health andlongevity where everyone could live long, comfortably and healthily, while challenging
to solve social problems such as impending situation of health financing and burdening
care.

<About Cyberdyne>
Since its establishment as a venture company from the University of Tsukuba in 2004, Cyberdyne
has promoted the comprehensive development of various Cybernic Systems (Cybernic devices,
Cybernic interfaces, etc.) that utilize Cybernic Technology from research and development to social
implementation, aiming to tackle the various issues facing society. The company has developed
business in the fields of medicine, welfare and daily living (including the work environment), and its
main product, Robot Suit HAL®, is widely distributed not only in the medical and welfare fields but
also in care support and labor support fields. In addition, new products such as Transportation Robotand Cleaning Robot equipped with artificial intelligence and environment recognition functions, HAL
Lumbar Type for reduction of the load and stress on the lower back, smaller-sized HAL (Single-JointType), Vital Sensor for arteriosclerosis and arrhythmia measurements are continuously developed. For
more details, please refer to the following website: www.cyberdyne.jp/eng/.

<About CureApp>
CureApp, Inc. is a MedTech venture company that researches, develops andmanufactures Medical devices and software with“Treatment Application” based on
medical evidence. To realize the first medical service of “clinically effective application
on improvement of diseases” in Japan, CureApp develops a “Treatment Application” formobile devices. Based on the information input by the patient, the “TreatmentApplication” will analyze and provide sufficient guidance that is backed-up withmedical knowledge and evidence. As the application might influence the patientʼsawareness, action and daily habits, it is probable that the conditions of the patient
would improve. CureApp, Inc. became the first Japanese company to start the clinical
trial for Treatment Application, which is currently in progress. CureApp, Inc. is also
working on Treatment Application for other diseases in order to become the global
digital health solution provider that is originated in Japan.